3-Amino-1-Adamantanol CAS 702-82-9 Purity >99.0% (HPLC) Factory

Short Description:

Chemical Name: 3-Amino-1-Adamantanol 

CAS: 702-82-9

Appearance: White Crystalline Powder

Purity: >99.0% (HPLC) (dry basis) 

Intermediate of API (CAS 274901-16-5) in the treatment of Type 2 Diabetes Mellitus (T2DM)

Inquiry: alvin@ruifuchem.com


Product Detail

Related Products

Product Tags

Description:

Chemical Properties:

Chemical Name 3-Amino-1-Adamantanol 
Synonyms 1-Amino-3-Hydroxyadamantane; 3-Amino-1-Hydroxyadamantane
CAS Number 702-82-9
CAT Number RF-PI102
Stock Status In Stock, Production Capacity 800MT/Year  
Molecular Formula C10H17NO
Molecular Weight 167.25
Solubility  Soluble in Organic Solvents and Insoluble in Water
Brand Ruifu Chemical

Specifications:

Item Specifications
Appearance White Crystalline Powder
Purity / Analysis Method >99.0% (HPLC) (dry basis)
Water (by Karl Fischer) <0.50%
Residue on Ignition <0.50%
Melting Point 266.5℃~272.5℃
Single Impurity <0.50%
Total Impurities <1.00%
Infrared Spectrum Conforms to Structure
Test Standard Enterprise Standard
Usage Intermediate of API (CAS: 274901-16-5)

Package & Storage:

Package: Bottle, Aluminium foil bag, 25kg/Cardboard Drum, or according to customer's requirement

Storage Condition: Store in sealed containers at cool and dry place; Protect from light & moisture

Advantages:

10

FAQ:

121

Application:

Shanghai Ruifu Chemical Co., Ltd. is the leading manufacturer and supplier of 3-Amino-1-Adamantanol (CAS: 702-82-9) with high quality. API (CAS: 274901-16-5) is synthesised from 3-Amino-1-Adamantanol. API (CAS: 274901-16-5) is an oral anti-hyperglycemic agent (anti-diabetic drug) of the new dipeptidyl peptidase-4 (DPP-4) inhibitor class of drugs. API (CAS: 274901-16-5) inhibits the inactivation of GLP-1 and GIP by DPP-4, allowing GLP-1 and GIP to potentiate the secretion of insulin in the beta cells and suppress glucagon release by the alpha cells of the islets of Langerhans in the pancreas. It has been shown to reduce hyperglycemia in type 2 diabetes mellitus. It was approved in Feb 2008 by European Medicines Agency for use within the EU and is listed on the Australian PBS with certain restrictions.

  • Write your message here and send it to us